URGN — UroGen Pharma Ltd.

UroGen Pharma Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $27.5 million, comprising $25.7 million from JELMYTO and $1.8 million from ZUSDURI.
• JELMYTO Revenue Growth: 13% increase year-over-year, excluding $2.6 million in CREATES Act sales from the same period in 2024.
• Net Loss: $33.3 million, or $0.69 per share, compared to a net loss of $23.7 million, or $0.51 per share in Q3 2024.
• Cash Position: $127.4 million as of September 30, 2025.
• R&D Expenses: $14 million, up from $11.4 million in Q3 2024, primarily due to costs associated with the UGN-103 trial.
• SG&A Expenses: $37.6 million, an increase from $28.9 million in the prior year, driven by ZUSDURI commercial preparation and sales force expansion.

2. Strategic Updates and Business Highlights

• ZUSDURI Launch: Initial uptake slower than anticipated due to logistical challenges and reimbursement issues. However, October's preliminary demand revenue of $4.5 million indicates a doubling of adoption compared to previous months.
• JELMYTO Performance: Continued strong demand with a solid clinical value and prescriber confidence.
• Clinical Advancements: UGN-103's NDA submission is planned for the second half of 2026, with potential approval in 2027. UGN-501 is in IND-enabling studies, with a Phase I trial expected in 2026.
• Market Access: Broad coverage achieved for ZUSDURI across major payers, with over 95% of covered lives.

3. Forward Guidance and Outlook

• JELMYTO Revenue Guidance: Expected net product revenues for 2025 in the range of $94 million to $98 million, reflecting 8% to 12% growth year-over-year.
• Operating Expenses: Guidance remains unchanged at $215 million to $225 million for 2025.
• ZUSDURI Adoption: Anticipated acceleration in adoption post-January 1, 2026, when a permanent J-code will simplify reimbursement processes.

4. Challenges and Points of Concern

• ZUSDURI Adoption Delays: Conversion from patient enrollment forms (PEFs) to actual dosing is taking longer than expected (45-60 days), primarily due to administrative hurdles and the temporary miscellaneous J-code.
• Net Loss Increase: The net loss has widened compared to the previous year, raising concerns about financial sustainability.
• UGN-301 Discontinuation: The program was halted due to insufficient clinical profile for advancement, redirecting focus to UGN-103 and UGN-501.

5. Notable Q&A Insights

• Physician Feedback: Many physicians are waiting for the permanent J-code before prescribing ZUSDURI, indicating a potential backlog of demand.
• Community vs. Institutional Treatment: Currently, 35-40% of ZUSDURI treatments are in community settings, with expectations for growth in this area once the J-code is active.
• Patient Enrollment Forms: Strong month-over-month growth in PEFs, with current numbers comparable to JELMYTO, suggesting healthy demand.
• Cash Position and Future Needs: Management believes current cash reserves are sufficient to reach profitability, but will remain disciplined regarding future capital needs.

Overall, UroGen Pharma is navigating a challenging launch environment for ZUSDURI but remains optimistic about long-term growth potential, particularly with the upcoming permanent J-code and ongoing clinical advancements.